In the largest all-cash pharma takeover in history and the largest-ever all-cash acquisition of a pre-profitability company in any industry, S&C is advising Seagen in Pfizer’s $43 billion acquisition of the biotech innovator. The deal, which stands as the largest of any M&A deal announced thus far in 2023, will double Pfizer’s pipeline of early stage cancer treatments.
Seagen is a pioneer in antibody-drug conjugate technology, a chemotherapy that attacks cancer cells while minimizing harm to healthy cells. Pfizer’s acquisition of Seagen, which has four commercial cancer treatments and a deep pipeline of cancer treatments in development, will accelerate the next generation of cancer breakthroughs.
The cross-border team advising Seagen includes lawyers from our New York, Palo Alto, Washington, D.C., and Brussels offices. The team is led by Matt Hurd, Melissa Sawyer and Brad King, and includes Michael Fronk, Alex Bavis, Rachel Weiss and Jin Lee. Matt Friestedt, Sarah Remmer Long and Julia Paranyuk are advising on executive compensation matters. Renata Hesse, Samantha Hynes, Karl Bock and Daniel Richardson are advising on U.S. antitrust matters. Michael Rosenthal, Kolja Ortmann and Penelope Bergkamp are advising on global competition matters. Rachel Yu and Grace Son are advising on intellectual property matters. Davis Wang, Anna Erickson and Alexei Owen are advising on tax matters. Eric Kadel and Manon Scales are advising on trade compliance matters. Matthew Brennan is advising on environmental matters.
Our multidisciplinary Healthcare & Life Sciences practice delivers best-in-class services to clients of all sizes, from start-ups to investment funds to the largest global healthcare businesses. We have advised on some of the largest and most innovative recent deals in this sphere, including Amgen’s $28.3 billion acquisition of Horizon Therapeutics, Abiomed’s $18 billion pending acquisition by J&J, Biohaven Pharmaceuticals’ $11.6 billion acquisition by Pfizer, Baxter International’s $12.4 billion acquisition of Hillrom, and Haleon's demerger from GSK and landmark European listing creating the world's biggest stand-alone consumer health company.
Related Content